Metformin for treatment of type 2 diabetes: use is extended to patients with moderately reduced kidney function
2016.11.03
Active substance: metformin
As of 14 October 2016 and based on a European safety review, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended further lowering the limit of the creatinine clearance above which metformin is contraindicated.
For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):